Home/Pipeline/Stempeucel®

Stempeucel®

Knee Osteoarthritis

CommercialApproved

Key Facts

Indication

Knee Osteoarthritis

Phase

Commercial

Status

Approved

Company

Stempeutics Research, Stempeutics Research, Stempeutics Research, Stempeutics Research

About Stempeutics Research

India‑based MSC biotech delivering approved cell‑therapy products and a growing pipeline of regenerative medicines.

View full company profile

About Stempeutics Research

India‑based MSC biotech delivering approved cell‑therapy products and a growing pipeline of regenerative medicines.

View full company profile

About Stempeutics Research

India‑based MSC biotech delivering approved cell‑therapy products and a growing pipeline of regenerative medicines.

View full company profile

About Stempeutics Research

India‑based MSC biotech delivering approved cell‑therapy products and a growing pipeline of regenerative medicines.

View full company profile

Therapeutic Areas

Regenerative Medicine Cell Therapy Orthopedics Vascular Medicine Dermatology

Other Knee Osteoarthritis Drugs

Drug	Company	Phase	Status
Progenza	Cambium Bio	Phase 1/2a	Active
MAG200	Magellan	Phase 3	Active
MUTI™ Knee Replacement	Meril	Commercial	Active
DUROLANE	Bioventus	Commercial	Active
XSTEM	Xintela	Phase I/IIa	Completed (Results Reported)
Lipogems System for Knee Osteoarthritis	Lipogems International	Phase 3	Active
Signature Cord Prime™	Arugula Sciences	Phase 1	Active
Knee Osteoarthritis Study	Arizona Research Center	Not Specified	Active - Enrolling
4P004	4Moving Biotech	Phase 2a	Active
Lorecivivint (inferred)	Biosplice Therapeutics	Phase 3	Active
Regenerative Cell Therapy for Osteoarthritis	InGeneron	Phase 3	Active
ArthroCart	Arthro Biotech	Preclinical	Active